Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deucravacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 known ✓ | P29597 | 19/20 | 0.98 |
| ▸ | JAK2 | O60674 | 4/20 | 0.98 |
| ▸ | JAK1 | P23458 | 2/20 | 0.98 |
| ▸ | STAT3 | P40763 | 1/20 | 0.98 |
| ▸ | STAT1 | P42224 | 1/20 | 0.98 |
| ▸ | JAK3 | P52333 | 1/20 | 0.98 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deucravacitinib SCHEMBL29375597 | 1.00 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29424395 | 0.99 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL20520348 | 0.99 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29619500 | 0.98 | TYK2 (0.98) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672334 | 0.96 | TYK2 (0.94) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672326 | 0.95 | TYK2 (0.92) | TYK2JAK2JAK1STAT3STAT1 | |
| Cravacitinib SCHEMBL21091048 | 0.93 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Cravacitinib SCHEMBL30465860 | 0.93 | TYK2 (1.00) | TYK2JAK2JAK1STAT3STAT1 | |
| Deucravacitinib SCHEMBL29672335 | 0.92 | TYK2 (0.90) | TYK2JAK2JAK1STAT3STAT1 | |
| SCHEMBL22288341 | 0.91 | TYK2 (0.85) | TYK2JAK2JAK1STAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291517-B2 | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-06 | — | — | US | disclosed |
| CN-118994118-A | Crystalline forms of a compound | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994117-A | Crystalline forms of a compound | 百时美施贵宝公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230242515-A1 | CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-03 | — | — | US | disclosed |
| US-11613529-B2 | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242515-A1 | CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3, TUBA3C | TYK2 839/4885JAK2 3140/4885JAK1 2583/4885 |
| US-12291517-B2 | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-D3) pyridazine-3-carboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3, TUBA3C | TYK2 839/4885JAK2 3140/4885JAK1 2583/4885 |
| US-11613529-B2 | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TUBA3C, H1-3 | TYK2 703/4885JAK2 3077/4885JAK1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.